secwatch.observer — SEC 8-K summary
======================================

Issuer:     LEXICON PHARMACEUTICALS, INC. (LXRX)
CIK:        0001062822
Form:       8-K
Filed at:   2024-05-10T23:59:59+00:00
Accession:  0001062822-24-000029
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 3.02, 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lexicon converts all preferred to 115M common; authorized shares increased to 450M
--------------------------------------------------------------------------------

- 2,304,147 shares of Series A Preferred automatically converted into 115,207,350 common shares on May 10, 2024.
- Authorized common stock increased from 300M to 450M via Sixth Amended and Restated Certificate of Incorporation.
- Stockholders elected Philippe Amouyal, Lonnel Coats, and Diane Sullivan as Class III directors with >241M votes each.
- Ratified charter amendment, approved executive compensation, and reappointed Ernst & Young as auditor for FY2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1062822/000106282224000029/0001062822-24-000029-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1062822/000106282224000029/lxrx-20240510.htm
  HTML page:      https://secwatch.observer/filing/0001062822-24-000029

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer